CY1110398T1 - Ενωσεις για την αγωγη της δυσλιπιδαιμιας - Google Patents

Ενωσεις για την αγωγη της δυσλιπιδαιμιας

Info

Publication number
CY1110398T1
CY1110398T1 CY20081101030T CY081101030T CY1110398T1 CY 1110398 T1 CY1110398 T1 CY 1110398T1 CY 20081101030 T CY20081101030 T CY 20081101030T CY 081101030 T CY081101030 T CY 081101030T CY 1110398 T1 CY1110398 T1 CY 1110398T1
Authority
CY
Cyprus
Prior art keywords
unions
disease education
education
disease
sequelae
Prior art date
Application number
CY20081101030T
Other languages
English (en)
Inventor
Michael Gregory Bell
Guoqing Cao
Ana Maria Escribano
Maria Carmen Fernandez
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Herranz Ana Isabel Mateo
Daniel Ray Mayhugh
Xiaodong Wang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1110398T1 publication Critical patent/CY1110398T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση αποκαλύπτει ενώσεις τύπου Ι στον οποίο τα A, n, m, j, q, Κ, W, Χ, Κ, Ζ, R1, R2, R3, R4, R5 και R6 είναι όπως ορίζονται εδώ και τις φαρμακευτικές συνθέσεις τους και μεθόδους χρήσεως ως χρήσιμες για την αγωγή της δυσλιπιδαιμίας και των συνεπειών της.
CY20081101030T 2004-03-26 2008-09-24 Ενωσεις για την αγωγη της δυσλιπιδαιμιας CY1110398T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22
EP05732643A EP1732933B1 (en) 2004-03-26 2005-03-17 Compounds for treating dyslipidemia

Publications (1)

Publication Number Publication Date
CY1110398T1 true CY1110398T1 (el) 2015-04-29

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101030T CY1110398T1 (el) 2004-03-26 2008-09-24 Ενωσεις για την αγωγη της δυσλιπιδαιμιας

Country Status (21)

Country Link
US (2) US20070208003A1 (el)
EP (2) EP1735320B1 (el)
JP (1) JP2007530550A (el)
KR (1) KR20070007112A (el)
AT (2) ATE433984T1 (el)
AU (1) AU2005230915A1 (el)
BR (1) BRPI0508966A (el)
CA (1) CA2557010A1 (el)
CY (1) CY1110398T1 (el)
DE (2) DE602005014955D1 (el)
DK (1) DK1732933T3 (el)
EA (1) EA200601785A1 (el)
EC (1) ECSP066886A (el)
ES (2) ES2326326T3 (el)
IL (1) IL177962A0 (el)
MA (1) MA28550B1 (el)
NO (1) NO20064763L (el)
PL (1) PL1732933T3 (el)
PT (1) PT1732933E (el)
SI (1) SI1732933T1 (el)
WO (2) WO2005097805A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
PL1732933T3 (pl) * 2004-03-26 2008-12-31 Lilly Co Eli Związki do leczenia dyslipidemii
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
WO2006012093A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
EP2229356B1 (en) 2007-12-03 2011-10-12 Novartis AG 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EP2231601B1 (en) * 2007-12-12 2014-06-18 Amgen Inc. Glycine transporter-1 inhibitors
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
MA33358B1 (fr) 2009-05-15 2012-06-01 Novartis Ag Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011064376A1 (en) 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
EP3130343B1 (en) * 2010-02-24 2018-05-09 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants
RU2012152320A (ru) 2010-05-06 2014-06-20 АЛЬФАКОР ФАРМА ЭлЭлСи Доставка эфиров холестерина в стероидогенные ткани
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
RU2609200C2 (ru) 2011-07-08 2017-01-30 Новартис Аг Способ лечения атеросклероза у субъектов с высоким уровнем триглицеридов
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
JPWO2013080999A1 (ja) 2011-11-29 2015-04-27 興和株式会社 ＮＰＣ１Ｌ１及び／又はＬＩＰＧｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MX367525B (es) 2013-02-14 2019-08-26 Novartis Ag Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
EP0970082A2 (en) * 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
DK1533292T3 (da) 2002-08-30 2007-06-04 Japan Tobacco Inc Dibenzylaminforbindelse og medicinsk anvendelse deraf
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
PL1732933T3 (pl) 2004-03-26 2008-12-31 Lilly Co Eli Związki do leczenia dyslipidemii
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
WO2006012093A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Also Published As

Publication number Publication date
US20070173526A1 (en) 2007-07-26
DE602005014955D1 (de) 2009-07-30
JP2007530550A (ja) 2007-11-01
EP1735320B1 (en) 2009-06-17
SI1732933T1 (sl) 2008-10-31
EP1732933B1 (en) 2008-07-23
ATE402180T1 (de) 2008-08-15
ES2326326T3 (es) 2009-10-07
IL177962A0 (en) 2006-12-31
US20070208003A1 (en) 2007-09-06
MA28550B1 (fr) 2007-04-03
KR20070007112A (ko) 2007-01-12
AU2005230915A1 (en) 2005-10-20
EP1735320A1 (en) 2006-12-27
ECSP066886A (es) 2006-11-24
WO2005097805A1 (en) 2005-10-20
BRPI0508966A (pt) 2007-08-21
US7470705B2 (en) 2008-12-30
PT1732933E (pt) 2008-10-20
WO2005097806A1 (en) 2005-10-20
ES2308477T3 (es) 2008-12-01
ATE433984T1 (de) 2009-07-15
NO20064763L (no) 2006-11-22
PL1732933T3 (pl) 2008-12-31
EP1732933A1 (en) 2006-12-20
DE602005008416D1 (de) 2008-09-04
DK1732933T3 (da) 2008-10-27
EA200601785A1 (ru) 2007-02-27
CA2557010A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CY1110398T1 (el) Ενωσεις για την αγωγη της δυσλιπιδαιμιας
DK1836201T3 (da) Pyrrolidininhibitorer af IAP
SE0302811D0 (sv) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
TW200626579A (en) Inhibitors of the interaction between MDM2 and p53
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
SE0202133D0 (sv) Novel compounds
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200801199A1 (ru) Ингибиторы киназы
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
SE0303541D0 (sv) New compounds
TW200740781A (en) Novel compounds
MA28268A1 (fr) Composes et techniques de traitement de la dyslipidemie
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
SE0303090D0 (sv) Novel compounds
TW200745053A (en) 9-Aminocarbonylsubstituted derivatives of glycylcyclines